Pfizer Expects Vaccine Will Be “Durable Revenue Stream” As It Seeks Approval For Children 2 To 11
May 5th, 2021Never Forget: Pfizer Agrees to Pay Largest Healthcare Fraud Penalty in History
Via: ZeroHedge:
Yesterday, Pfizer released a strong earnings report (surpassing Wall Street’s elevated projections), and also revealed that it’s both on the cusp of securing regulatory approval in the US for minors between the ages of 12 and 15 to receive the vaccine (setting off another wave of demand as the Biden Administration heaps pressure on states to get their vaccination numbers up).
During a call with analysts and reporters, CEO Albert Bourla revealed that Pfizer is in talks with “basically all the governments of the world” about providing shots and booster shots through 2024.
The key number is that Pfizer expects sales of its coronavirus jab to hit $26 billion by the end of this year, a milestone that would make the vaccine the company’s biggest-selling pharmaceutical product, eclipsing Humira, the popular rheumatoid arhtritis drug made by Abbvie. Also, Pfizer said it intends to use its mRNA technology underpinning its COVID-19 jab for other therapies and vaccines. For example, the company is working on creating seasonal flu shots using the same RNA lipid nanoparticle technology.
…
According to recent media reports, Pfizer is also seeking approval for the vaccine to be used on children as young as 2 and as old as 11 in both the US and Europe, an authorization it expects to arrive in September.
